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Abstract –The increased adipose tissue mass of obese individuals enhances the risk of 
metabolic syndrome, type 2 diabetes and cardiovascular diseases. During pathological 
expansion of adipose tissue, multiple molecular controls of lipid storage, adipocyte turn-
over and endocrine secretion are perturbed and abnormal lipid metabolism results in a 
distinct lipid profile. There is a role for ceramides and sphingosine 1-phosphate (S1P) in 
inducing adipose dysfunction. For instance, the alteration of ceramide biosynthesis, 
through the de-regulation of key enzymes, results in aberrant formation of ceramides (e.g. 
C16:0 and C18:0) which block insulin signaling and promote adipose inflammation. 
Furthermore, S1P can induce defective adipose tissue phenotypes by promoting chronic 
inflammation and inhibiting adipogenesis.   These abnormal changes are discussed in the 
context of possible therapeutic approaches to re-establish normal adipose function and 
to, thereby, increase insulin sensitivity in type 2 diabetes.  Such novel approaches include 
blockade of ceramide biosynthesis using inhibitors of sphingomyelinase or 
dihydroceramide desaturase and by antagonism of S1P receptors, such as S1P2. 
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Introduction 
 
Type 2 diabetes (T2D) is a multifactorial metabolic disorder that results in hyperglycaemia due 
to the resistance of peripheral tissues to insulin and the failure of pancreatic β cells to secrete 
insulin; the latter is termed β cell decompensation [1,2]. 392 million people were diagnosed 
with T2D in 2015 and the prevalence of the disease is estimated to rise globally to approx. 600 
million by 2035 [3,4]. Insulin resistance is a pathological condition that develops early in the 
disease and precedes the onset of hyperglycaemia and hyperinsulinemia, thereby affecting the 
endocrine control of peripheral tissue metabolism [2,5]. Meta-analyses of patient populations 
indicate that the relative risk of developing the disease is much higher in obese and overweight 
individuals compared with those with a normal BMI [6,7]. However, not all obese patients 
develop insulin resistance or diabetic complications (termed healthy obesity) [8,9]. The 
pathogenesis of T2D involves a dysfunctional adiposity phenotype, which includes excess 
visceral fat, chronic inflammation and insulin resistance [10–12]. The risk of pre-diabetes and 
T2D is increased by visceral obesity rather than general adiposity [13]. The defective function 
of adipose tissue constitutes a mechanistic link between obesity and T2D. For instance, 
hyperglycaemia and hyperlipidaemia arising from excess adiposity can interfere with insulin 
signaling and cellular metabolism in non-adipose tissue (termed glucolipotoxicity), which 
eventually results in chronic inflammation, insulin resistance and abnormal islet function [14–
19].  In addition, the abnormal secretion of inflammatory cytokines and adipokines from 
dysregulated adipose tissue accelerates systemic inflammation and promotes peripheral insulin 
resistance [20]. Therefore, adipose dysfunction in obesity appears to have a significant role in 
the development of systemic insulin resistance in T2D and metabolic syndrome. 
 
Preventive therapy that slows the onset and reverses the progression of T2D requires an 
improved understanding of the basic molecular biology of adipose tissue in response to the 
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imbalance between food intake and energy expenditure. Sphingolipids are a class of cellular 
lipids containing a sphingoid base and various head groups, many members of which (e.g. 
ceramide and sphingosine 1-phosphate (S1P)) are emerging players in metabolic syndrome, 
obesity and T2D [21,22]. In this regard, ceramide and S1P regulate a myriad of cellular events, 
such as insulin signaling, inflammatory responses and intracellular metabolism in an organ-
specific manner [23–25]. Therefore, this review focuses on the role of ceramide/S1P 
metabolism and signaling in dysregulated adipose tissue function under conditions of surplus 
dietary energy intake.  
 
Physiological role of adipose tissue in whole-body metabolism 
Adipose tissue is composed of various cell types, including adipocytes, pre-adipocytes, 
mesenchymal stem cells and immune cells (e.g. adipose tissue macrophages, ATM), along with 
different cellular compositions of fat depots.  These fat depots are found  in distinct anatomical 
locations which determine their special physiological properties [26,27]. The primary cell type 
within white adipose tissue is the white adipocyte, which contains a large high energy lipid 
droplet. In contrast, adipocytes of brown adipose tissue contain large mitochondria with a high 
level of uncoupling protein-1 (UCL-1) that results in more extensive lipid oxidation to generate 
heat, thereby enabling thermogenic regulation [1]. Interestingly, white adipocytes can be 
transdifferentiated into brown-like adipocytes (known as beige adipocyte) with thermogenic 
capacity in response to cold and β-adrenergic receptor stimulation [28,29]. Adipocyte 
progenitor cells from the adipose tissue stromal fraction are responsible for maintaining the 
normal ‘turn-over’ of adipocytes [28,30], while there is also a spectrum of immune cells 
(including M1 and M2 macrophages), which are involved in adipose remodeling and in 
regulating insulin sensitivity [31,32].  
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White adipose tissue maintains normal metabolism by absorbing and exporting fat and glucose 
in a non-oxidative pathway during feeding and fasting respectively, thereby meeting the 
physiological demand between meals. The esterification of glycerol with non-esterified fatty 
acids (NEFA) produces triacyglycerol (TAG), which is then packaged into the lipid droplet 
inside the white adipocyte. The lipolytic pathway in adipocytes is tightly controlled by the 
neuroendocrine system and circulating nutrient molecules.  These modulate the expression and 
activity of lipid droplet-associated proteins and lipid hydrolytic enzymes (e.g. hormone-
sensitive lipase (HSL), adipose triglyceride lipase (ATGL) and monoglyceride lipase (MAGL)) 
and which are regulated by cAMP- and cGMP-dependent signaling pathways [33]. For 
example, the interaction of perilipin1, the predominant protein associated with the lipid droplet, 
and HSL can be enhanced by the protein kinase A (PKA) catalysed phosphorylation of 
perilipin1, which increases the enzymatic activity of HSL [34,35]. In addition, PKA can 
directly phosphorylate HSL and induce its association with the lipid droplet [36]. Another 
important function of adipose tissue is the endocrine control of whole-body metabolism and 
appetite and this is achieved by regulating production of adipokines, pro-inflammatory 
cytokines (e.g.MCP-1, TNFα and interleukin-1β) and adipocyte-specific hormones (e.g. leptin, 
adiponectin and vaspin). Circulating adiponectin enhances energy consumption and 
lipid/glucose metabolism in the liver and skeletal muscle whereas leptin, acting in the 
hypothalamus, reduces appetite [20].  
 
The lipolytic/lipogenic pathways in adipose tissue are fine-tuned to regulate circulating glucose 
and lipid levels and this is controlled by the endocrine and neuronal systems [33,37]. High fat 
diet (HFD) challenge in the short term does not cause adipose dysfunction or systemic 
metabolic defects because the expansion and redistribution of fat depots compensate for the 
lipid burden in metabolically active tissues [38]. Indeed, pre-adipocyte differentiation and 
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proliferation (hyperplasia) and existing adipocyte enlargement (hypertrophy) in fat depots 
enables functional plasticity of the adipose tissue that is in positive caloric balance [39]. The 
upregulation of the transcription factors such as peroxisome proliferator-activated receptor 
gamma (PPARγ), CCAAT/enhancer-binding proteins (C/EBPs) and sterol regulatory element-
binding transcription factor 1 (SREBF1) and inhibition of Wnt/β-catenin signaling promotes 
differentiation of pre-adipocytes into lipid-storing adipocytes.  This results in the expression of 
adipocyte-specific genes including the glucose transporter type 4 (GLUT-4) and fatty acid-
binding protein 4 (FABP4) that maintain glucose and lipid homeostasis [28,40,41]. Considering 
the beneficial role of PPARγ and other transcription factors involved in TAG biosynthesis, de 
novo adipogenesis ensures normal glucose/NEFA metabolism in adipose tissue and maintains 
overall insulin sensitivity during subcutaneous expansion [40]. Indeed, the disruption of 
adipogenesis in adipocyte-specific Stat3-/-  mice leads to increased general adiposity, reduced 
energy expenditure and high liver TAG levels [42].  
 
Visceral adipose expansion through increased lipid filling is dependent on adipocyte 
enlargement, which results from a high expression of anti-adipogenic genes  such as Gata2 and 
Tgfb2 allied with reduced expression of pro-adipogenic genes such as Pparg, Bmp2 and Bmp4. 
[43,44]. Indeed, the enlargement of fat cells leads to increased hormone-induced lipolysis and 
suppressed insulin-stimulated lipid and glucose uptake [45–48]. Furthermore, up-regulation of 
pro-inflammatory cytokines (e.g. TNFα and MCP-1) and altered secretion of adipokines (e.g. 
adiponectin and leptin) are evident in hypertrophic adipocytes [20,49–51]. Therefore, while 
adipogenesis is the predominant form of adaptation to accommodate over-nutrition, 
hypertrophy is likely to be involved in promoting insulin resistance and hyperlipidaemia 
thereby leading to diabetic complications [39,52–54]. This is supported by the finding that 
hypertrophic obesity is associated with suppressed adipogenic rates in pre-adipocyte [55]. Of 
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note, there is different sensitivity of pre-adipocytes to adipogenic stimuli in different fat pads. 
For example, adipogenesis during the development of obesity is much higher in subcutaneous 
adipose tissue compared with visceral compartments, and this results in the distinct changes in 
adipocyte size, number and metabolism [54]. Intriguingly, the hypertrophic adipocyte, with 
exhausted storage capacity, in visceral regions is associated with derangement of lipid 
metabolism and the development of dyslipidemia [56]. Furthermore, subcutaneous adipose 
hypertrophy correlates with impaired insulin signaling and glucose handling, suggesting the 
pathological effects of adipose hypertrophy are also depot-specific [56].  
 
The lipid overload and excess TAG deposition in adipose tissue leads to impaired adipogenesis 
and increased adipocyte hypertrophy. This is characterized by a hyper-lipolytic and pro-
inflammatory phenotype that is resistant to insulin [1,2]. The increased secretion of MCP-1 
from hypertrophic adipocytes initiates the recruitment and proliferation of ATMs, which 
subsequently release chemokines and cytokines that promote chronic inflammation [20,57,58]. 
In addition, the release of TNFα and IFNγ from macrophages, T cells and NK cells inhibits the 
differentiation of pre-adipocytes and reduces insulin signaling in mature adipocytes [59,60].  
Therefore, the lipolytic pathway in hypertrophic adipocytes is further amplified by chronic 
inflammation and insulin resistance. As a result, the increased NEFA and lipid metabolites 
delivery from dysfunctional adipose tissue overwhelms the oxidation rate to cause ectopic fat 
deposition in the heart, liver and skeletal muscle and this leads to the onset of systemic 
metabolic disease [10]. A good example of this is the increase in NEFA influx in skeletal muscle 
and liver that results in higher intracellular diacylglycerol (DAG) levels, which activate protein 
kinase C (PKC) isoforms, PKCθ and PKCε, that can functionally abrogate insulin signaling 
[61].  
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Dyslipidaemia involves a large number of different lipids, which arise from dysregulated lipid 
metabolism pathways in adipose tissue. TAG and NEFA become elevated in plasma and high 
levels of circulating ceramide in T2D patients appear to contribute to the development of 
peripheral insulin resistance [62].  It is not surprising then, that the reduction in whole body 
and abdominal adiposity after physical exercise is associated with decreased plasma ceramide 
levels and improved systemic insulin sensitivity in T2D patients [63]. The elevation of 
circulating S1P levels in obese animal models and T2D patients is positively associated with 
central abdominal obesity and metabolic syndrome [64–66], thereby suggesting a relationship 
between ceramide/S1P metabolism, adipose dysfunction and T2D.  However, whether this 
represents a causal mechanism is currently unknown. 
 
Insulin resistance of adipose tissue   
Insulin regulates glucose and fat metabolism in metabolically active tissues through canonical 
insulin-dependent signaling to reduce plasma concentrations of NEFA and glucose. At the 
molecular level, insulin activates the insulin receptor (IR) tyrosine kinase, which catalyses the 
tyrosine phosphorylation of itself and IR substrate (IRS). The latter acts as cytosolic adaptor 
protein, enabling recruitment and activation of phosphoinositide 3-kinase (PI3K) and thereby 
elevation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), an activator of 
phosphoinositide-dependent kinases (PDK) which,  together with the mTOR complex 2 
(mTORC2), catalyses the phosphorylation of protein kinase B (PKB/AKT) on Thr308 and 
Ser473. The downstream effectors of AKT modulate insulin-induced metabolism; these include 
effects on the glucose transporter, GLUT-4, lipid synthesis (e.g. SREBP1c) and gluconeogenic 
and lipogenic enzyme expression (e.g. FOXO) [67]. In addition, the insulin-induced activation 
of the Ras/mitogen-activated protein kinase (MAPK) pathway via IRS regulates cell growth 
and differentiation. A complex and integrated network is formed by the extensive cross-talk 
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between insulin-, leptin-, insulin growth factor-1- and inflammatory cytokine-mediated 
signaling pathways to modulate reversible phosphorylation cascades and 
transcriptional/translational programmes [67,68].  
 
Insulin regulates glucose transportation, glycolysis and glycogen synthesis in adipose tissue 
[69]. At a molecular level, insulin activates cAMP phosphodiesterase 3B (PDE3B), 
downstream of AKT to reduce intracellular cAMP levels thereby, blocking PKA-induced 
lipolysis.  Other proteins that limit lipolysis include protein phosphatase-1 (PP-1) which, when 
stimulated by insulin, deactivates HSL via a cAMP-independent mechanism [35,70,71]. Insulin 
also transcriptionally suppresses ATGL and thereby accelerates TAG accumulation via 
inhibition of the nuclear translocation of Forkhead box protein O1 (FOXO1) [70,72]. PPARγ-
mediated adipogenic programmes via activation of the AKT/mTORC1 pathway are also 
stimulated by insulin [38,73].  Finally, the insulin-dependent activation of MAPK pathways 
promotes the stimulation of transcriptional factors, such as Med23 and Elk1; key regulators of 
adipogenesis [74]. Indeed, the inducible deletion of  phosphatase and tensin homolog (PTEN), 
which catalyses the dephosphorylation of PIP3 in mature adipocytes results in enhanced insulin 
signaling to potentiate adipogenesis and to reduce adipose inflammation during the long-term 
HFD insult [75]. Therefore, the maintenance of normal adipose tissue function provides many 
whole-body metabolic advantages, such as low liver fat accumulation and improved glucose 
tolerance in adult mice [75].   
 
The ectopic lipid deposition in obesity and resulting from excess NEFA influx establishes a 
large lipid metabolite pool in adipose tissue [18]. Consequently high DAG and ceramide levels 
activate PKCε and PKCζ respectively, which catalyse inhibitory serine/threonine 
phosphorylation of IR and IRS to block insulin signaling [17,18]. Concurrent with lipid-
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mediated insulin resistance, inflammatory mediators, such as TNFα, IL-1β and IL-6, derived 
from adipocytes and ATM, stimulate c-Jun N-terminal kinases (JNKs), inhibitor of nuclear 
factor kappa-B kinase subunit β (IKKβ), ribosomal protein S6 kinase (S6K) and the 
mammalian target of rapamycin (mTOR).  This results in the serine phosphorylation of IRS-1, 
which reduces insulin signaling [19,67,76]. It is also significant in the context of insulin 
resistance that TNFα and IFNγ  increase expression of the suppressor of cytokine signaling 3 
(SOCS3) which is a specific inhibitor of IRS [77–79] (Figure 1). 
 
Lipid oversupply and activation of PKC can also induce IKK- and JNK-dependent 
phosphorylation of IRS and IR, thereby stimulating pro-inflammatory STAT-1 and NFκB-
dependent signaling and insulin resistance [80]. Moreover, saturated NEFAs are  ligands of 
Toll-like receptor 4 (TLR4) and are able to directly promote IKKβ and JNK activation in 
adipocytes [31,81]. The oversupply of glucose and lipid interferes with the oxidative system in 
mitochondria and protein synthesis in the endoplasmic reticulum (ER), thereby resulting in 
oxidative and ER stress respectively.  This is important because these stress pathways can 
induce activation of JNK-AP1 and IKKβ–NFκB, the transcription of pro-inflammatory genes 
[18,82–85] and the increase cytokine secretion in an autocrine and paracrine manner [5]. The 
net effect is that  extracellular pro-inflammatory mediator secretion induced by lipid overload 
accelerates the impairment of insulin sensitivity in a positive regulatory loop. For example, 
TNFα increases the hydrolysis of TAG through transcriptional, translational and post-
translational down-regulation of PPARγ [17] and the subsequent over-activation of the lipolytic 
programme exacerbates lipid burden and PKC-mediated insulin resistance in adipocytes. In 
most cases, lipid-mediated signaling and metabolic inflammatory pathways are therefore, 
interconnected and function in synergy to oppose insulin signaling (Figure 1).  
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Deregulation of ceramide biosynthesis in adipose tissue 
While the majority of NEFA is either oxidized in the mitochondria or stored as glycolipids, a 
small proportion is used for the biosynthesis of phospholipids and sphingolipids. Ceramide is 
a major hub of sphingolipid metabolism and is composed of sphingosine, a long-chain amino 
alcohol, with an N-linked fatty acyl group of various carbon chain lengths. Ceramide also 
constitutes the backbone of complex sphingolipids and can be converted into sphingosine, 
catalyzed by the enzyme, ceramidase. There is particular interest in ceramide because it can 
promote insulin resistance [86]. This is exemplified by studies showing that the treatment of 
3T3-L1 adipocytes with the cell permeant short chain C6-ceramide reduces GLUT4 
transcription and GLUT4 mRNA stability leading to impaired glucose uptake [87]. The 
underlying mechanism by which ceramide impairs glucose transport is linked with the 
dephosphorylation of AKT by protein phosphatase 2A (PP2A).  This is supported by the fact 
that PP2A is activated by ceramide [88–90].   PKCζ is also activated by ceramide and inhibits 
AKT recruitment and activation by catalyzing the phosphorylation of Thr34 in the PH-domain 
of AKT, thereby reducing binding of PIP3 to AKT [91,92]. Other mechanisms also operate as 
caveolar ceramide induces the association of PKCζ with AKT, the recruitment of PTEN and 
the retention of AKT within caveolin-enriched micro-domains (CEM) [93]. The PKCζ-AKT 
interaction represses AKT in CEM, and the localization of PTEN in these membrane domains 
enables dephosphorylation of PIP3 to prevent AKT activation [93].  Ceramide also stimulates 
the NLRP3 inflammasome to increase IL-1β levels [94] and enhances TNFα, MCP-1 and IL-
6 expression in adipocytes [95], which might contribute to chronic inflammation and the 
development of insulin resistance.   Finally, the blockade of ceramide synthesis results in the 
downregulation of MCP-1 and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue of 
diet-induced obese (DIO) rodent models [96]. Therefore, ceramide-mediated insulin resistance 
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is the result of an integrated inflammation and lipid signaling responses that are linked with the 
hallmarks of adipose dysfunction (Figure 2). 
 
Ceramide is formed by cellular compartment-specific mechanisms (Figure 3).  Therefore, 
alteration of these specific pathways may influence the intracellular distribution of ceramide. 
One key mechanism of ceramide production is via the ‘so-called’ de novo synthesis pathway 
on the ER.  The condensation of serine and palmitoyl Co-A by serine palmitoyltransferase 
(SPT), to produce 3-keto-sphinganine, is usually the rate limiting step in this biosynthetic 
pathway [97]. Therefore, the modulation of SPT activity can affect the profile of sphingolipid 
metabolites in cells [98]. This is exemplified by studies showing that SPT deficiency in adipose 
tissue results in reduced ceramide, sphingomyelin, S1P and sphinganine 1-phosphate levels and 
these changes are associated with impaired adipocyte development and adipocyte death [99]. 
The rapid conversion of 3-keto-sphinganine into sphinganine is catalyzed by 3-keto-
sphinganine reductase. A second fatty acid CoA is then incorporated into sphinganine to form 
dihydroceramide, catalysed by ceramide synthase (CerS).  Dihydroceramide is then desaturated 
by dihydroceramide desaturase (Degs1) to produce ceramide through the introduction of a 4, 5 
trans double bond. Six distinct CerS isoforms use different fatty acid CoAs to catalyse 
acylation of sphinganine to produce ceramides with different acyl chain lengths.  Specificity is 
determined by 11 amino acids in an N-terminal luminal loop of the enzyme [100]. The fatty 
acid CoAs range from C14:0 to C26:0 [21,101,102]. For example, the concerted action of Degs1 
and CerS2 results in the synthesis of ceramides with the very long acyl chains varying from 
C20:0 to C26:0, whereas CerS6 and Degs1 catalyse the formation of ceramides containing C14:0 
and C16:0 fatty acids [88,103]. In contrast, Degs1 and CerS4 catalyse the synthesis of C18:0 to 
C20:0 acyl chain ceramides [88,103]. The formation of C16:0 and C18:0 ceramides can lead to 
abnormalities in glucose hemostasis and lipid metabolism.  Indeed, the loss of CerS5 and CerS6 
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protects mice from HFD-induced obesity and insulin resistance [104–106]. Furthermore, 
ceramide, glucosylceramide and dihydroceramide containing stearate (C18:0) are associated 
with insulin resistance and inflammation in human skeletal muscle [107]. In contrast, the low 
expression of CerS2 in the liver of CerS2 heterozygous (CerS2-/+) mice leads to decreased 
levels of long-chain ceramides (i.e. C22:0, C24:0 and C24:1 ceramides) but there is also a 
compensatory increase in C16:0-containing sphingolipids in hepatocytes, which are associated 
with hepatic insulin resistance and mitochondrial respiratory chain disorders [108]. Degs1 is 
the last step in de novo ceramide synthesis and might play a key role in obesity.  In this regard, 
GWAS studies indicate that Degs1 is a pre-disposing gene for fat mass accumulation [109]. 
This is supported by evidence showing that genetic deletion of the Degs homologue in 
Drosophila results in high levels of dihydroceramides and increased fat storage [110]. 
 
The acid and neutral sphingomyelinases (aSMase and nSMase) hydrolyse membrane 
sphingomyelin into ceramide and phosphocholine [86]. Deficiency in aSMase underlies the 
lysosomal storage Niemann-Pick disease where there is accumulation of sphingomyelin in 
lysosomes. Intriguingly, the low body weight of Niemann-Pick patients might indicate that 
aSMase has a role in regulating fat depots. This is supported by results demonstrating that mice 
with deletion of aSMase (Smpd1-/-) cannot accumulate fat in liver and adipose tissue [111]. The 
lysosomal recycling of complex sphingolipids, such as sphingomyelin or glucosylceramide 
produces ceramide, which is rapidly deacylated to sphingosine and NEFA. This sphingosine 
can be resynthesized into ceramide by CerS or phosphorylated to S1P by sphingosine kinases 
(SphK) [23,112]. The intracellular levels of ceramide do not remain constant but undergo 
temporal and spatial fluctuations due to different rates of metabolism, which is likely to 
determine impact on insulin sensitivity and adipose function [88,90].  
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The infusion of circulating saturated lipid into adipose tissue provides substrates to produce 
ceramide and other sphingolipids because the metabolic flux through SPT is dependent on the 
availability of palmitate [97,113]. For example, NEFA is used for ceramide biosynthesis in 
human skeletal muscle [114]. However, the ability of lipid oversupply, through de novo 
ceramide synthesis, to affect adipose tissue dysfunction is confounded by the finding that the 
exposure of 3T3-L1 adipocytes to palmitate does not enhance ceramide synthesis and does not 
affect insulin sensitivity [89]. Nevertheless, there is substantial evidence that ceramide 
synthesis is, indeed, upregulated in adipose tissue during inflammation [115,116]. This was 
demonstrated by the intraperitoneal administration of the inflammatory mediator TNFα, which 
stimulates ceramide synthesis in adipose tissue by increasing the expression of aSMase, 
nSMase, and SPT in C57/BL6 mice [95]. In addition, pro-inflammatory lipids, such as 
palmitate, and lipopolysaccharides (LPS) activate TLR4/IKKβ signaling and increase the 
expression of SPT2, CerS1, CerS2 and CerS6 and Degs1 linked with ceramide-induced insulin 
resistance in C2C12-derived myotubes [117]. Wild-type mice also have a higher C16:0 ceramide 
level in subcutaneous fat compared with mice carrying adipocyte-specific TLR4 deletion [118]. 
It has also been shown that the expression of sphingomyelinases is increased in inflamed 
adipose tissue of obese female patients [119]. However, there are no detectable changes in de 
novo ceramide biosynthesis in adipocytes and macrophages, thereby suggesting a more 
prominent role for the sphingomyelinase pathway [119]. Taken together, this evidence suggests 
that, in obesity, there might be a switch from the de novo ceramide pathway to the 
sphingomyelinase pathway in dysregulated adipose tissue. Indeed, it has been proposed that de 
novo ceramide synthesis is actually reduced as the expression of Degs1 mRNA is decreased  in 
white adipose tissue of HFD-fed and ob/ob mice [120]. 
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The expression level of CerS6 in visceral and subcutaneous fat depots is positively correlated 
with BMI in humans. This is significant as CerS6 regulates the formation of C16:0 ceramide in 
adipocytes of DIO mice [106] and this ceramide species is linked with adipose dysfunction and 
T2D.  Importantly, this might suggest that it is the formation of specific molecular species of 
ceramide in adipose tissue that promotes adipose dysfunction, even though the net production 
of ceramide by de novo synthesis is reduced.  
 
Recently, Siddique et al. [121] reported that mouse embryonic fibroblasts lacking Degs1 have 
increased dihydroceramide levels and enhanced AKT/protein kinase B (PKB) signaling, which 
is a pro-survival pathway that blocks apoptosis.  In addition, Degs1-/- cells exhibited high levels 
of autophagy as a result of impaired ATP synthesis and activation of AMP-activated protein 
kinase (AMPK).  Therefore, Degs1 deletion is associated with the induction of both anabolic 
and catabolic signaling pathways.  We propose that these findings suggest that there might be 
two populations of Degs1, which are functionally opposed.  The first population is native 
Degs1 which catalyses formation of ceramides which, we propose, act to block AKT/PKB 
signaling.  Thus, removal of Degs1 will increase anabolic AKT signaling and this might 
contribute to sensitisation of cells to insulin.  In addition, we have shown that Degs1 is subject 
to polyubiquitination in HEK293T cells and PANC1 cancer cells [122].  Therefore, the second 
population of Degs1 might be represented by these polyubiquitinated forms, which we have 
shown exhibit a ‘gain of function’ and appear to have a different substrate specificity compared 
with the native form [122].  Alternatively, these polyubiquitinated forms might be relocated to 
specialized lipid micro-domains with access to specific dihydroceramides.  The 
polyubiquitinated forms of Degs1 are linked to positive regulation of p38 MAPK [122], which 
is an inhibitor of autophagy [123].  Therefore, loss of polyubiquitinated forms of Degs1 might 
increase autophagy because of the reduction in p38 MAPK signaling.  We have also shown that 
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the native Degs1 is pro-apoptotic while the polyubiquitinated forms promote cell survival [122].  
Genetic deletion of Degs1 will eliminate both native and polyubiquitinated forms, and it is 
possible that deficiency of the native form has a predominant effect in promoting cell survival 
[121] (Figure 4). 
 
In contrast with the findings described above, the shRNA mediated decrease in Degs1 
expression in 3T3-L1 cells increases the dihydroceramide/ceramide ratio and reduces 
adipogenic and lipogenic programmes [120]. The down-regulation of Degs1 reduces PPARγ 
activity and cyclins, such as D1, D3, E, as well as decreasing cdk2, which regulate PPARγ 
activity during adipogenesis.  These findings are correlated with adipose dysfunction in 
diabetic patients as the levels of dihydroceramide are higher compared with non-diabetic  
controls [124]. 
 
Targeting ceramide biosynthesis in adipose tissue 
 
High content of DAG and ceramide, together with increased macrophage infiltration are found 
in subcutaneous adipose tissue of obese women with increased liver fat [125], suggesting that 
ceramide might also amplify chronic inflammation and insulin resistance in adipose tissue 
[125].  In addition, the levels of ceramides including C14:0, C16:0, C16:1 and C18:1 species are 
elevated in the white adipose tissue of obese and diabetic patients [106,124,126,127] and  C16:0 
and C18:0 ceramides levels are increased in adipose tissue of HFD-fed mice and are correlated 
with the development of adipocyte-specific insulin resistance [128]. The adipose tissue of 
C57BL mice on long-term HFD (16 or 18 weeks) also have increased C16:0 and C18:0  ceramide 
levels but decreased C24:0 ceramide [106,129]. Indeed, in a large multi-ethnic Dallas Heart 
Study, plasma short-chain saturated ceramides, such as C16:0 and C18:0 were positively linked 
with insulin resistance, dyslipidemia and visceral adiposity. In contrast, plasma 
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polyunsaturated ceramides (C24:2, C30:10 and C32:11) were inversely associated with these 
unfavorable phenotypes [130]. These findings suggest that C16:0 and C18:0 ceramides are linked 
with de-regulated adiposity. Nevertheless, there is still some controversy regarding the role of 
ceramides in adipose dysfunction. Thus, while SPT, aSMase, and nSMase mRNA levels are 
increased in obese human subcutaneous and abdominal adipose tissue, ceramide accumulation 
does not occur [131].  However, this might be explained by increased expression of acid and 
alkaline ceramidase, which might rapidly convert these ceramides into sphingosine [95]. It is 
also worth noting that, despite no overt increase in ceramide levels, subtle changes in certain 
ceramide species in subcellular compartments might be sufficient to induce abnormalities in 
metabolism and insulin signaling [132,133].   
 
Targeting the biosynthesis of ceramide shows promising results in restoring normal adipose 
function. For instance, DIO mice treated with myriocin, a potent inhibitor of SPT, results in a 
decrease in intracellular ceramide levels and an increase in the expression of thermogenic and 
browning/beiging genes in white adipose tissue [124].  The consequence of this is to direct 
adipocytes into a metabolically active state with increased glucose uptake and lipid oxidation, 
potentially arising from normalization of insulin sensitivity [124]. The loss of adipocyte-
specific SPT2 also recapitulates this phenotype and improves mitochondrial activity [124]. 
Furthermore, pharmacological blockade or genetic loss of SPT suppresses chemokines and 
cytokines expression and promotes an anti-inflammatory M2 macrophages phenotype in fat 
depots [96,124]. In addition, mice deficient in CerS6 and challenged with HFD exhibit reduced 
C16:0 ceramide levels in white and brown adipose tissue. This results in suppressed adipose 
inflammation and increased β-oxidative capacity [106].  Additional support for this concept, is 
that the elevation of C16:0 ceramide levels induced by HFD in epididymal white adipose tissue 
is reduced in Cers5-/- mice compared with wild type littermates. This results in upregulation of 
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C/EBPα and PPARγ that promote adipogenesis concomitant with down-regulation of pro-
inflammatory genes [134]. The role of Degs1 has been investigated using the Degs1 inhibitors, 
fenretinide and GT-11. Fenretinide blocks ceramide accumulation in liver and skeletal muscle 
and prevents peripheral insulin resistance and hepatic steatosis in DIO mice [135]. Fenretinide 
also improves adipokine profiles, with increased levels of adiponectin and resistin and 
decreased levels of leptin and retinol binding protein 4 (RBP4) [136]. Paradoxically, the Degs1 
inhibitor, GT-11 blocks rosiglitazone (PPARγ agonist)-induced adipocyte differentiation [120] 
and exogenous dihydroceramides interfere with the early phase of adipocyte differentiation. 
The implication of these findings is that Degs1 inhibitors might worsen the adipocyte 
phenotype in obesity [120]. However, the action of GT-11 is somewhat different from genetic 
loss of Degs1 as AKT or AMPK signaling in response to insulin is unaltered. Furthermore, the 
action of GT-11 is distinct from fenretinide, which does not block rosiglitazone-induced 
adipocyte differentiation. Fenretinide also normalises mitochondrial metabolism as indicated 
by the low level of TCA cycle intermediates and oxidative stress markers, in white adipocyte 
of HFD-fed mice. In common with the Degs1−/−, fenretinide induces autophagy in mature 
adipocytes, indicating that its mechanism of action is recapitulated [121].  This is further 
supported by studies using a metabolite of fenretinide, 4-oxo-N-(4-hydroxyphenyl)retinamide 
(termed 4-OXO), which is also  a potent inhibitor of Degs1 [137] and has poor effects on 
retinoic acid receptor.  Significantly, 4-OXO does not inhibit adipogenesis of 3T3-L1 
adipocytes [138], but instead increases the expression level of adipogenic markers.  In addition, 
4-OXO promotes AKT phosphorylation and autophagy induction independent of retinol gene 
modulation [138].  These findings raise the question as to why GT-11 and fenretinide have 
distinct mechanisms of action yet both target Degs1.  We propose that this difference might be 
due to the ability of fenretinide, but not GT-11 to induce the polyubiquitination of Degs1, which 
inhibits autophagy by promoting p38 MAPK signaling [122]. However, polyubiquitinated 
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Degs1 will eventually be degraded by the proteasome, which, if fast in adipocytes, might result 
in the loss of Degs1 in response to fenretinide.   This would then recapitulate the effects of 
genetic loss of Degs1 on AKT signaling and autophagy [121].  These studies highlight the need 
to more fully understand the role of Degs1 in adipose dysfunction.  It is therefore, important to 
know whether different classes of Degs1 inhibitors are anti-adipogenic or pro-adipogenic as 
highlighted by issues raised from use of GT-11 versus fenretinide   However, the balance of 
the data, in our opinion favours the use of Degs1 inhibitors that induce proteasomal degradation 
of Degs1 to treat T2D.  This is supported by evidence showing that Degs1+/- mice exhibit 
normal glucose levels and enhanced insulin sensitivity and are refractory to dexamethasone-
induced insulin resistance compared with wild type littermates [139]. 
 
Additional evidence to support a role for ceramide in adipose dysfunction comes from studies 
in which the deletion of Smpd1, encoding aSMase, has been reported to be protective against 
HFD-induced hyperglycemia and insulin resistance in mice lacking LDL receptor [111]. Ldlr-
/- mice with Smpd1 deletion fed on a HFD exhibit exhibit reduced adipose and liver fat 
accumulation compared with Smpd1+/+/Ldlr-/- littermates. These effects are recapitulated by 
the aSMase inhibitor, amitriptyline, which reduces plasma ceramide and attenuates adiposity, 
insulin resistance and glomerular injury in HFD C57BL/6J mice [140]. Finally, the genetic loss 
of Smpd1 prevents adipocyte hypertrophy and promotes brown adipose tissue differentiation 
via a mechanism involving alterations in gene expression of adipocytes in Western diet-fed 
mice [141]. The improvement in adipose tissue function contributes to diminished liver 
steatosis [141]. 
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S1P metabolism and signaling  
Sphingosine-1-phosphate (S1P) is a bioactive lipid that appears to have an important role in 
obesity and T2D. S1P levels are governed by the availability of sphingosine, and the catalytic 
activity of S1P metabolising enzymes e.g. sphingosine kinases (SphK), S1P phosphatase and 
S1P lyase. Ceramidases catalyse the deacylation of ceramide to produce sphingosine which can 
be phosphorylated, using ATP, by two isoforms of sphingosine kinase, SphK1 and SphK2, to 
produce S1P.  These isoforms  are encoded by two different genes and regulate overlapping 
and non-overlapping signaling pathways [142]. Their differing protein sizes, tissue and 
subcellular localisations and biochemical properties determine their differing biological roles 
in physiological and pathophysiological states [25,143].  
 
In response to extracellular stimuli, such as growth factors or inflammatory mediators, the 
catalytic activity of SphK1 can be increased by an ERK-1/2-catalysed phosphorylation of 
Ser225 in the R-loop [144]. ERK-1/2 is downstream of growth factor receptor tyrosine kinases 
(e.g. EGFR and VEGFR), TNF receptors and PKC [145–147]. Ser225 phosphorylation 
stimulates the translocation of cytosolic SphK1 to the plasma membrane where the enzyme can 
access sphingosine [144,148].  Intracellular S1P confers E3 ligase activity to TRAF2 to activate 
the NFκB pathway [149,150] and can bind to PPARγ to induce transcriptional activity in 
endothelial cells [151]. Similarly, epidermal growth factor (EGF) and the PKC activator, 
phorbol 12-myristate 13-acetate (PMA) promote activation of SphK2 via ERK-1-catalysed 
phosphorylation of Ser351 and Thr578 [152,153]. SphK2 is also regulated by a PKD catalysed 
phosphorylation of its nuclear export motif, which causes its export from the nucleus to the 
cytoplasm [154,155], thereby altering its subcellular localisation.  In the nucleus SphK2 is 
associated with histone H3 and histone deacetylase 1 and 2 (HDAC-1/2) and the subsequently 
formed S1P inhibits HDAC1/2-catalysed deacetylation of histone H3 to up-regulate the 
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expression of cyclin dependent kinase inhibitor p21 and the transcriptional regulator c-fos 
[156].  In addition, S1P produced by mitochondrial SphK2 binds to prohibitin 2 to facilitate the 
assembly of respiratory complex IV and to thereby regulate oxidative phosphorylation in the 
inner mitochondrial membrane [157].  
 
However, S1P is also released from cells through cell-specific transporters (e.g. ATP-binding 
cassette transporters and the spinster 2 transporter) and is an agonist of S1P-specific G protein-
coupled receptors (a family of five, termed S1P1-S1P5). S1P1 couples exclusively with Gi and 
inhibits adenylyl cyclase, while S1P4 and S1P5 couple to Gi and G12/13 [158,159]. S1P2 and 
S1P3 have a broader G protein coupling specificity and interact with Gi, Gq and G12/13 [158,160]. 
S1P receptors coupled to Gi/Gq activate phospholipase C (PLC) and promote the elevation of 
intracellular Ca2+ [161]. The activation of S1P1 decreases intracellular cAMP levels and 
stimulates the Ras/ERK-1/2 and PI3K/AKT pathways to promote cell survival [158]. S1P 
binding to S1P1 also induces PI3K/Rac pathway to stimulate cytoskeletal rearrangement and 
cell migration [162]. In contrast, signaling through G12/13 results in the activation of Rho to 
inhibit cell motility [163]. Therefore, S1P1 and S1P2 are functionally opposed in regulating cell 
migration [164,165].   
 
Intracellular S1P is either irreversibly cleaved into phosphoethanolamine and hexadecenal by 
S1P lyase, which represents the only exit point of sphingolipid metabolism [166], or is 
dephosphorylated to sphingosine by S1P-specific phosphatases [167].  Sgpl-/- mice exhibit 
increased levels of several sphingolipids (S1P, ceramide and sphingomyelin) and other lipid 
metabolites (cholesterol and phospholipid) in serum. Moreover, the absence of S1P lyase is 
associated with altered expression of key genes involved in lipid metabolism in the liver, such 
as Sptlc1/2 and PPARγ [168]. Lipid phosphate phosphatases (LPPs) can also catalyse 
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dephosphorylation of  S1P, thereby regulating the levels of this bioactive lipid in intracellular 
and extracellular compartments [169,170]. The overexpression of LPP1 also downregulates 
typical PKC isoform expression to suppress GPCR and receptor tyrosine kinase signaling [171].  
 
S1P and insulin signaling in adipocytes  
S1P levels in adipocytes are significantly elevated in obese patients and SphK1/S1P signaling 
in adipocytes is increased in obese and T2D rodent models [126,172].  The effect of S1P on 
cellular response is regulated by the ‘so-called’ sphingolipid-rheostat, which involves inter-
conversion of ceramide, sphingosine and S1P.  Ceramide generally induces cell 
apoptosis/senescence and S1P promotes proliferation/survival pathways [173,174]. Therefore, 
the balance of this rheostat might determine cell fate.  This is exemplified by studies showing 
that the stimulation of SphK reduces ceramide levels to exert dramatic effects on cell survival, 
insulin signaling and gene expression [24]. Indeed, the overexpression of SphK1 in HFD-
treated transgenic mice improves insulin sensitivity in muscle [175]. In addition, glucose-
induced activation of SphK2 increases intracellular S1P enhances insulin secretion [176] and 
improves mitochondria homeostasis by modulating prohibitin expression in the pancreatic β 
cell [177]. S1P also promotes an anti-apoptotic effect in pancreatic β cells [178,179]. Two S1P 
receptor-like motifs in CerS2 are bound by S1P to inhibit its activity [180], which might prevent 
accumulation of ceramide within the sphingolipid rheostat, indicating that forward and 
backward reactions are likely reciprocally regulated. Furthermore, the over-expression of 
SphK1 enhances S1P formation in INS-1 β cells and prevents palmitate-induced apoptosis, 
accompanied by down-regulation of CerS4 to limit the synthesis of specific ceramide species 
via an S1P receptor-independent mechanism [181]. S1P also directly attenuates the pro-
apoptotic effect of ceramide in pancreatic β cells [181,182] and affects glucose homeostasis by 
increasing the rate of glucose uptake in 3T3-L1 adipocytes [183].  The bioactive lipid might 
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also have a role in leptin-deficient and DIO rodent models, where organ-specific over-
expression of adiponectin receptor in adipose and liver reduces C16:0 and C18:0 ceramides levels 
via an activation of ceramidase [184,185]. Increased ceramidase activity likely also contributes 
to a metabolically active state in adipose tissue [186] and removal of S1P by LPP3 is a key 
regulatory step in adipose function.  Thus, deletion of LPP3 ameliorates insulin resistance 
without altering TAG synthesis or adipocyte differentiation in HFD-feeding mice [187]. 
Interestingly, the elimination of LPP3 leads to down-regulation of SPT and improves 
sphingolipid profiles with a reduction in ceramide and sphingomyelin and an increase in S1P 
levels in adipocytes. These findings reveal that the increase in the S1P/ceramide ratio in 
adipocytes might be potentially beneficial in maintaining or restoring insulin sensitivity. 
 
S1P also activates the PI3K/AKT pathway in cells; this therefore, might represent a convergent 
point with insulin signaling [188,189]. This is exemplified by the use of FTY720 phosphate 
(an analogue of S1P), which is an agonist of all S1P receptor types with the exception of S1P2.  
In the adipose tissue of DIO mice, FTY720 phosphate prevents the reduction in AKT-
dependent signaling caused by a HFD [190].  However, it should be noted that crosstalk 
between S1P receptors and canonical insulin signaling pathways results in different outcomes 
dependent on the cell type. For instance, in C2C12 skeletal muscle myoblasts, S1P2 activation 
induces the formation of reactive oxygen species which promotes the oxidation and enzymatic 
inhibition of protein-tyrosine phosphatase 1B (PTP1B), a major negative regulator of IR-
mediated signaling [191]. S1P also stimulates IR phosphorylation and increases glucose uptake 
in myoblasts [191] and expression of SphK2 and increased S1P levels are induced by ER stress 
leading to AKT phosphorylation in mouse primary hepatocytes [192].  This results in improved 
lipid metabolism as a consequence of increased expression of genes involved in fatty acid 
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oxidation [192]. In contrast, an opposing role for S1P involves S1P2, suppression of AKT 
phosphorylation and inhibition of glycogen synthesis in hepatocytes [193]. 
 
S1P and adipose tissue remodeling   
S1P functions as an important lipid mediator in regulating adipose distribution and whole-body 
fat mass; achieved by modulating lipolysis/lipogenesis and the pre-adipocyte 
differentiation/proliferation state (Table 1). SphK1 and SphK2 are upregulated during the 
hormone-stimulated differentiation of 3T3-L1 pre-adipocytes whereas pharmacological 
inhibition or gene silencing of SphK1 reduces lipid storage and adipogenesis [201,202].  Both 
SphK1 and SphK2 appear to regulate adipogenesis, while SphK1 also regulates the 
differentiation of pre-adipocytes. Even though the expression of SphK1 and SphK2 are 
increased with differentiation, their total enzymatic activity declines in the late phase of 
terminal differentiation [202]. In addition, mRNA expression levels of S1P1-3 are reduced 
during the late phase of adipogenesis and the addition of exogenous S1P cannot re-establish 
the adipogenic programme.  These findings suggest that S1P receptors might not be sufficient 
to influence the pre-adipocyte differentiation state under physiological conditions [202]. 
 
Even though SphK1/S1P promotes pre-adipocyte differentiation in in vitro models, there are 
reports of restricted adipose tissue expansion upon activation of specific S1P receptors.  In 
addition, S1P lyase deficiency reduces adiposity in mice fed on a normal diet [168].  Relevant 
to these issues is the finding that high concentrations of S1P can induce lipolysis through S1P 
receptor-linked cAMP-PKA signaling in cultured rat white adipocytes [194].  It is notable that 
cAMP formation in coronary artery smooth muscle cells is promoted by activation of S1P2, 
which induces arachidonic acid release.  In this case, S1P appears to promote an ERK-1/2–
dependent phosphorylation and activation of PLA2 which produces prostacyclin that can, in 
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turn, act on the PGI2 receptor (which is coupled via  Gs) to stimulate cAMP formation [203]. 
S1P also induces the down-regulation of adipocyte-specific transcriptional factors, such as 
PPARγ, C/EBPα and adiponectin, which abrogates adipogenesis to suppress lipid deposition in 
3T3-L1 pre-adipocytes [195]. This might be mediated by S1P2 receptor and JNK signaling 
[195], based on the finding that the adenoviral-mediated overexpression of S1P2 in 3T3‑L1 
pre-adipocytes inhibits the JNK pathway and induces down-regulation of PPARγ expression 
[200]. S1P also increases the expression of S1P2 during the differentiation of 3T3-L1 pre-
adipocytes and this is associated with the inhibition of adipogenesis and lipid accumulation 
[198].  In this regard, antagonism of S1P2, with JTE-013, abolishes the S1P-dependent 
downregulation of adipogenic genes [198] and increases the proliferation of 3T3-L1 pre-
adipocytes through the ERK-1/2 pathway [194].  The inhibitory role of S1P2 in regulating 
adipogenesis is further evident by the finding that epididymal adipocytes isolated from HFD-
fed S1pr2-/- mice proliferate and exhibit improved insulin sensitivity and glucose tolerance 
[199]. Furthermore, oral administration of the S1P2 antagonist, JTE-013 to ob/ob mice 
increases insulin sensitivity, accompanied by reduced adipocyte hypertrophy [199].   
 
Despite the evidence described above which identifies S1P2 as a potential therapeutic target, 
there are examples where the anti-adipogenic effects of S1P involve other S1P receptor types. 
This is based on the finding that FTY720 phosphate, which does not bind to S1P2, inhibits 
adipogenesis and promotes lipolysis in DIO mice, resulting in weight and fat mass loss [190]. 
Indeed, the major effect of FTY720 phosphate might be through internalization and persistent 
signaling of S1P1, which is subsequently degraded [204,205]. This functional antagonistic 
effect of FTY720 phosphate on S1P1 signaling leads to the sequestration of circulating T-
lymphocytes in lymph nodes and suppresses autoreactive T lymphocyte recirculation in, for 
instance, multiple sclerosis [206,207]. However, it is notable that the administration of low 
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dose FTY720 (0.04 mg/kg twice per week), that does not induce lymphopenia, promotes 
AKT/GSK3β and AMPK signaling and reduces adipogenesis in DIO mice.  S1P also inhibits 
early phase differentiation of C3H10T1/2 multipotent stem cells into adipocytes [196].  This 
involves an S1P1- and Gi-dependent decrease in cAMP levels, thereby inhibiting C/EBPβ, 
PPARγ and FABP4 expression [196]. The involvement of S1P1 is also evident from studies 
showing that the S1P1/3 antagonist, VPC-23019 induces the differentiation of 3T3-F442A pre-
adipocytes [199].  These findings are supported by the siRNA-mediated loss of S1P1 which 
promotes differentiation of 3T3-F442A pre-adipocytes [199]. The pro-lipolytic effect of 
FTY720 phosphate involves increased transcriptional regulation of HSL, ATGL and perilipin 
allied with increased Ser563 phosphorylation of HSL. These findings have been confirmed by 
in vitro experiments in 3T3-L1 adipocytes [190]. In addition, FTY720 promotes insulin 
resistance and reduces glucose uptake in mature adipocytes [208–210].  Although FTY720 is 
an activator of PP2A, this is likely excluded as a mechanism of action, because PP2A catalyses 
the dephosphorylation of HSL and inhibits hormone-stimulated lipolysis in an obese rodent 
model [211] 
 
In summary, S1P-mediated lipolysis in mature adipocytes reduces the lipid burden and limits 
adipose tissue expansion.  In contrast, the inhibition of pre-adipocyte differentiation, mediated 
by S1P1 or S1P2, reduces adaptive expansion of adipose tissue in response to positive caloric 
balance. Of note, high concentrations of S1P might activate cAMP/PKA via PGI2 to promote 
lipolysis and lipid release, whereas the inhibition of adipogenesis might involve S1P1/2.  These 
responses could potentially account for adipose dysfunction and peripheral insulin resistance. 
However, the biological functions of each S1P receptor subtype needs to be validated in vivo 
as cell models do not recapitulate the micro-environmental interaction of adipose tissue with 
the stromal vascular fraction under pathological conditions. Nevertheless, we propose that the 
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pro-inflammatory and hypertrophic phenotype of adipocytes under excess NEFA influx renders 
S1P more likely to inhibit adipogenesis and increase lipolysis.  
 
S1P and adipose inflammation  
SphK1/S1P regulate cytokines secretion and promote inflammatory responses in in vitro and 
in vivo models and these responses might also contribute to impaired adipogenesis leading to 
insulin resistance.  For instance, S1P promotes increased expression of pro-thrombotic proteins 
(e.g. PAI-1) and pro-inflammatory cytokines (e.g. TNF, IL-6, MCP-1 and keratinocyte-derived 
chemokine) in 3T3-L1 adipocytes [95] (Table 2).  Importantly, LPS also stimulates the up-
regulation of SphK1 in primary rat adipocytes and SphK1 activity this is positively associated 
with chemokine (C-C motif) ligand 5 (CCL5) levels in subcutaneous white adipose tissue in 
rats [212].  
 
The activation of β3 adrenoceptor (ADRB3)/HSL signaling also upregulates SphK1 via JNK- 
and activator protein-1 (AP-1)-dependent pathways to promote IL-6 secretion in white adipose 
tissue [213].  These findings suggest the involvement of S1P in regulating lipolysis-dependent 
IL-6 synthesis, release and local inflammation [213]. Consistent with this, the expression of 
anti-inflammatory mediators, such as IL-10 and adiponectin are elevated in epididymal adipose 
tissue of Sphk1-/- mice, which exhibit HFD-induced obesity [172] and decreased expression of 
pro-inflammatory mediators, such as TNF, IL-6, and MCP-1 [172]. In addition, deletion of 
Sphk1 in adipose tissue decreases expression of SOCS3 [172] leading to improved insulin 
sensitivity and glucose tolerance that is partly attributed to impairment of the inflammatory 
response [172]. Similarly, the use of SphK1/2 inhibitor, SPHK I (also known as SKI-II, 2-(p-
Hydroxyanilino)-4-(p-chlorophenyl) thiazole) on lean Zucker rats prevents LPS-induced up-
regulation of CCL5, IL-6, pentraxin 3 (Ptx3) and TNFα in subcutaneous white adipose tissue 
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[212]. The up-regulation of cytokine production can also be abolished by silencing SphK1 in 
3T3-L1 cells [212]. These findings suggest an interesting parallel with colitis-associated cancer 
cell biology, where the up-regulation of SphK1 expression increases the production of S1P, 
which persistently activates the canonical NFκB activation pathway, leading to enhanced IL-6 
formation and STAT3 activation [214]. Therefore, a SphK1/S1P1/STAT3 axis may amplify the 
inflammatory response and promote insulin resistance in adipose tissue  through a regulatory 
loop. 
 
S1P also regulates immune cell trafficking and re-circulation [215,216]. The administration of 
FTY720 (acting as FTY720 phosphate after its phosphorylation by SphK2) down-regulates 
S1P1 receptor expression in C57BL/6 DIO mice and this prevents the recruitment of circulating 
monocytes into adipose tissue, thereby reducing the presence of pro-inflammatory M1-
macrophages [204]. FTY720 also decreases adipose tissue lymphocytes and increases the 
presence of CD11c-negative, anti-inflammatory macrophages, which is associated with 
increased insulin sensitivity [204]. S1P might also contribute to M1 macrophages-mediated 
inflammatory responses in the adipose tissue microenvironment. This is supported by 
histological analysis of epididymal fat tissues isolated from HFD-fed S1pr2-/- mice, which 
exhibit a low level of M1 macrophage infiltration.  However, wide-type littermates on HFD 
exhibit many crown-like structures, which are formed by M1 macrophages that surround dying 
or dead adipocytes [199].  
 
SphK1 is also up-regulated in M1 macrophages from DIO and ob/ob rodent models and 
palmitate-induced lipotoxicity in mouse macrophage-like RAW264.7 cells is associated with 
increased SphK1 activity and enhanced survival of a macrophage population with a pro-
inflammatory phenotype [217]. These findings demonstrate that S1P derived from adipose not 
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only acts as a chemoattractant for macrophages and monocytes but also facilitates the 
polarization of adipose-derived anti-inflammatory M2 macrophages into a pro-inflammatory 
M1 phenotype.   
 
Taken together, modulation of the sphingolipid rheostat in adipose tissue might suggest that 
SphK1/2 can remove harmful ceramide.  However, the S1P formed has the potential to promote 
inflammation and to inhibit adipogenesis, thereby representing a key mechanism for adipose 
dysfunction in T2D.  It is possible that increased SphK activity, accompanied by S1P signaling, 
initially reduces accumulation of TAG and ceramide in adipose tissue, thereby reducing the fat 
burden on adipocytes. However, the inhibition of adipogenesis via S1P receptor-dependent 
mechanism(s) appears to direct adipocytes into a dangerous hypertrophic phenotype.  The 
S1P/SphK1 pathway also initiates an inflammation cascade by promoting the secretion of pro-
inflammatory cytokines, which ablate adipogenesis [20]. Notably, up-regulation of pro-
inflammatory genes and the participation of immune cells is enhanced during the transition 
from acute to chronic inflammation in adipose tissue [218]. As macrophage-mediated adipose 
inflammation is a key component in HFD-induced insulin resistance, M1 macrophage 
recruitment and polarization in response to S1P might have a very significant role in inducing 
adipose malfunction [57,218]. 
 
Conclusion 
It has been proposed that depleting intracellular ceramide levels might represent an attractive 
therapeutic strategy for treatment of T2D and obesity [219]. Considering the involvement of 
glucosylceramide and sphingomyelin in the acquisition of glucose intolerance and insulin 
resistance [21], S1P appears to be a less harmful product of ceramide metabolism in skeletal 
muscle, liver and pancreatic β cells (Figure 5). However, S1P/S1P2 signaling impairs insulin 
29 
 
action, glycogen synthesis and hepatic cell regeneration in the liver. This suggests that 
therapeutic antagonism of the S1P2 receptor might be a more attractive therapeutic strategy 
[193,220]. S1P is also pro-inflammatory and has a role in IL-6-induced insulin resistance [221].  
The activation of S1P receptors, especially S1P1 and S1P2, impairs adipogenesis and promotes 
the secretion of cytokines that indirectly block adipocyte differentiation and insulin signaling. 
S1P also has a role in macrophage recruitment and polarization that promotes adipose 
dysfunction during chronic inflammation.  
 
It must be kept in mind that the interactions between adipose tissue and the circulatory system 
are important in whole-body homeostatic control of metabolism. On the one hand, the lipid 
spill over from adipose tissue may contribute to the high circulating ceramide levels in obese 
individuals. In addition, NEFA from de-regulated adipose tissue can be utilized for sphingolipid 
biosynthesis in metabolically active tissues, which results in ceramide formation in the liver 
and skeletal muscle [218]. In addition, the adipose tissue itself is a potential source of 
circulating ceramides [115] and S1P derived from adipose tissue also promotes systemic 
inflammation in obesity.  The majority of plasma S1P is associated with apoM rich high-density 
lipoproteins (HDL) with small quantities binding to low-density lipoproteins (LDL) or very-
low-density lipoproteins (VLDL) [222,223]. ApoM deficiency in mice results in defective S1P1 
and S1P3 signaling in the endothelium and brown adipose tissue respectively and this leads to 
enhanced TAG metabolism and brown adipose development [224]. These findings suggest that 
the binding of circulating HDL-S1P to S1P receptors in brown adipose tissue might be 
responsible for restricting metabolic activity [224,225]. As there are high levels of circulating 
S1P and ceramide levels in obese and diabetic individuals, the pathological actions of blood-
borne bioactive lipids on adipose metabolism and inflammation should not be neglected [62,64].  
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The pharmacological intervention strategies targeting adipose function are limited and it is 
possible that tissue specific effects might be required. Since ceramide has a significant role in 
metabolic syndrome and cardiovascular diseases [226], it is reasonable to speculate that 
targeting adipose ceramide in T2D and obesity is a worthwhile therapeutic approach. The 
inhibition/loss of key enzymes (e.g. Degs1 inhibitors) that directly contribute to ceramide 
synthesis might effectively attenuate negative effects on insulin sensitivity. In addition, the 
upregulation of the sphingomyelinase pathway in dysfunctional adipose tissue provides a 
rationale for the use of sphingomyelinase inhibitors. Functional inhibitors of acid 
sphingomyelinase (FIASMA), a large group of pharmacological compounds with diverse 
chemical structures, can insert into the inner membrane of lysosomes, thereby removing the 
membrane-bound aSMase, which is then degraded within lysosomes [227,228]. However, 
pharmacological manipulation of sphingolipid metabolism by converting ceramide into 
sphingosine and, subsequently, S1P does not seem to hold promise.  A greater understanding 
of the precise actions of each S1P receptor subtype in adipose tissue is required to validate their 
full therapeutic potential and provide impetus for novel treatment strategies in T2D. 
Nevertheless, we conclude that the blockade of the S1P receptor signaling system, such as S1P1 
and S1P2, might provide therapeutic utility by restoring adipogenesis and inhibiting 
inflammation to re-establish normal adipose tissue function and insulin sensitivity in T2D 
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Abbreviations: 
ADRB3, β3-adrenergic receptor; AKT, protein kinase B; AMSC, adipose tissue-derived 
mesenchymal stem cell; ApoM, apolipoprotein M; AP1, activator protein 1; aSMase, acid 
sphingomyelinase; αSMA, α-smooth muscle actin; ATGL, adipose triglyceride lipase; ATM, 
adipose tissue macrophages; BMI, body mass index; BMP, bone morphogenetic protein; 
CCL5, chemokine ligand 5; C/EBPs, CCAAT/enhancer-binding proteins; CEM, caveolin-
enriched micro-domains; CerS, ceramide synthase; CL, CL-316243 (β3-adrenergic agonist); 
DAG, diacylglycerol; Degs1, dihydroceramide desaturase; DIO, diet-induced obesity; DMS, 
dimethylsphingosine; DHS, dihydrosphingosine,; EGF, epidermal growth factor; ER, 
endoplasmic reticulum; ERK1/2, extracellular signal-regulated kinase 1 and 2; FABP4, fatty 
acid-binding protein 4;  FOXO, forkhead box protein O; FTY-720, fingolimod (2-Amino-2-[2-
(4-octyl-phenyl)-ethyl]-propane-1,3-diol); GLUT4, glucose transporter 4; GSK3β, glycogen 
synthase kinase 3 beta; GWAS, genome-wide association study; HDAC1/2, histone 
deacetylase 1 and 2; HDL, high density lipoprotein; HFD, high fat diet; HSL, hormone-
sensitive lipase; IFNγ, interferon gamma; IL-1β, interleukin-1β;  IKK-β, inhibitor of nuclear 
factor kappa-B kinase subunit beta; IR, insulin receptor; IRS, insulin receptor substrate; JAK, 
Janus kinases; c-JNK, c-Jun N-terminal kinase; JTE-013, S1P2 antagonist; KC, keratinocyte-
derived chemokine; LDL, low density lipoprotein; LPP, lipid phosphate phosphatase; LPS, 
lipopolysaccharides; MAGL, monoglyceride lipase; MAPK, mitogen-activated protein kinase; 
MCP-1, monocyte chemoattractant protein 1; mTOR, mammalian target of rapamycin; NEFA, 
Non esterified fatty acid; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
NLRP3, NACHT, LRR and PYD domains-containing protein 3; nSMase, neutral 
sphingomyelinase; PCNA, proliferating cell nuclear antigen; PDE3B, phosphodiesterase 3B; 
PDK, phosphoinositide-dependent kinases; PHB2, prohibitin 2; PMA, phorbol 12-myristate 
13-acetate; PI3K, phosphoinositide 3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; 
PKA, protein kinase A; PKC, protein kinase C; PKD, protein kinase D; PLC, phospholipase 
C; PPARγ, peroxisome proliferator-activated receptor gamma; PP2A, protein phosphatase-2A; 
PTEN, phosphatase and tensin homologue; PTP1B, protein-tyrosine phosphatase 1B; S1P, 
sphingosine 1-phosphate; S1P1-5, S1P receptor 1-5; S6K, ribosomal protein S6 kinase; SPHK 
I or SKI-II (2-(p-Hydroxyanilino)-4-(p-chlorophenyl) thiazole); Smpd1, acid 
sphingomyelinase gene; SphK, sphingosine kinase; SOCS3, Suppressor of cytokine signaling 
3; SPT, serine palmitoyl transferase; SREBF1, sterol regulatory element-binding transcription 
factor 1; STAT3, signal transducer and activator of transcription 3; T2D, type 2 diabetes; TGFβ, 
transforming growth factor beta; TLR, Toll-like receptors; TNFα, tumor necrosis factor alpha; 
TRAF2, TNF receptor‑associated factor 2; UCL-1, uncoupling protein-1; VEGF, vascular 
endothelial growth factor; VLDL, very low density lipoprotein; VPC23019, S1P1/3 antagonist; 
ZLC, Zucker lean normoglycemic control; 5c, 2,2-dimethyl-4S-(1-oxo-2-hexadecyn-1-yl)-1,1-
dimethylethylester-3-oxazolidine-carboxylic acid. 
 
Figure Legends 
Figure 1. Pro-inflammatory and lipid signaling act synergistically in insulin resistance. 
The increased NEFA influx causes the elevation of diacylglycerol and ceramide levels in 
adipocytes and which activate PKCε and PKCζ respectively. These PKC isoforms not only 
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catalyse inhibitory serine/threonine phosphorylation of IR and IRS but also activate other 
protein kinase pathways, such as JNK, which are additionally regulated by inflammatory 
mediators, ER stress and ROS. The activation of JNK, IKKβ, S6K and mTOR induce up-
regulation of SOCS3 that antagonizes IRS to block insulin responsiveness. Pro-inflammatory 
mediators, such as TNFα, IFNγ and saturated fatty acid also promote upregulation of IL-6 and 
TNFα, which suppress PPARγ to inhibit lipogenesis and interfere intracellular metabolism 
through transcriptional and post-transcriptional regulation.   
 
Figure 2. Ceramide metabolism modulation and action in adipocyte.  Ceramide is a key 
lipid metabolite that reduces AKT-mediated signaling and responsiveness to insulin. Glucose 
transport is impaired by intracellular ceramide, which activates PP2A and PKCζ. PP2A 
dephosphorylates Ser473-phosphorylated AKT and blocks insulin receptor signaling.  PKCζ 
interrupts the recruitment of AKT and PTEN, retaining AKT in caveolin-enriched micro-
domains of the plasma membrane by phosphorylating Thr34 in AKT. Ceramide increases 
NLRP3 inflammasome activity; which stimulates conversion of pro-IL1β into IL-1β, to 
promote insulin resistance. The accumulation of ceramides is promoted by the activation of 
TLR4 and TNFR. In the contrast, the binding of adiponectin to adiponectin receptor1/2 induces 
ceramidase activity and accelerates ceramides metabolism. 
 
Figure 3. Ceramide biosynthesis.  The de novo ceramide synthesis pathway occurs in the 
endoplasmic reticulum and is initiated by serine palmitoyl transferase, the activity of which is 
affected by the availability of substrates, palmitate and serine. After a series of reactions, 
ceramide is generated in ER and is transported the Golgi apparatus for further biosynthesis of 
complex sphingolipids. Sphingomyelinase catalyses the hydrolysis of complex sphingolipids 
to produce ceramide in different sub-cellular compartments. The key metabolic enzymes that 
may play a role in adipose dysfunction in obesity are highlighted in red. The genetic deletion 
and pharmacological inhibition of these enzymes improve adipose metabolism and insulin 
sensitivity.  
 
Figure 4.  Role of native and polyubiqitinated forms of Degs1 in regulating 
anabolic/catabolic signaling.  Native Degs1 which is pro-apoptotic can be polyubiquitinated 
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to a form which has pro-survival function.  We propose here that these forms might account for 
the anabolic/catabolic phenotype of fibroblasts in which Degs1 expression has been eliminated.  
In this case, the native form of Degs1 might be responsible for the synthesis of ceramides which 
can block Akt signaling and thereby induce insulin resistance.  In contrast, the 
polyubiquitinated forms are linked with p38 MAPK signaling that functions to reduce 
autophagy by phosphorylation of ULK1.  We propose that certain Degs1 modulators such as 
fenretinide and 4-oxo-N-(4-hydroxyphenyl)retinamide but not GT-11 induce the ubiquitin-
proteasomal degradation and loss of Degs1, which recapitulates the phenotype in fibroblasts 
where Degs1 has been genetically eliminated. 
 
Figure 5. Ceramide and S1P function in concert to promote adipose dysregulation. 
Excessive fatty acid influx and inflammation promotes ceramide accumulation through the 
upregulation of enzymes involved in ceramide synthesis in adipose tissue to disrupt insulin 
signaling. The upregulation of pro-inflammatory genes can be induced by ceramide and can 
amplify the inflammatory responses in adipose tissue. The increased production of ceramide 
and upregulation of SphK1 contribute to the enhanced S1P formation.  The binding of S1P to 
S1P1/2 also reduces adipogenesis to hinder adaptation of adipose tissue to excessive fat 
deposition. The SphK1/S1P/S1PR axis is also involved in pro-inflammatory cytokines 
secretion and macrophages recruitment and differentiation. The direct consequence is the 
chronic inflammation that leads to adipose dysfunction and insulin resistance. 
Table 1.  S1P and downstream signaling in adipocyte metabolism and differentiation   
Cell type 
or animal 
Intervention Downstream signal Biological 
outcome 
Ref 
(rat) white 
adipocyte 
 
S1P 
(1–30 µM, 20 m*) 
↑ cytosolic Ca2+ and 
cAMP  
↑ lipolysis  
↓ insulin-induced 
leptin production 
[194] 
3T3-L1 
adipocytes 
S1P 
(5µM, 10 m) 
Not detected  ↑ glucose uptake [183] 
3T3-L1 
adipocytes 
S1P 
(0.5-50 µM, during 
adipogenesis) 
↓ PPARγ, C/EBPα and 
adiponectin  
↓ P-JNK1/2, P-p38 MAPK 
↓ adipogenesis  [195] 
C3H10T1/
2 cells 
 
S1P 
(0.1-1µM, 1-8 d) 
↓ cAMP, C/EBPβ, 
FABP4; ↓ PPARγ-driven 
transcription 
↓ adipogenic 
differentiation 
[196] 
AMSC S1P 
(1µM, 1-10 d) 
↑ αSMA/transgelin; 
↑ L-type and T-type Ca2+ 
currents  
↑ differentiation to 
smooth muscle 
phenotype  
[197] 
ASMC JTE-013 (1 µM) ↓ S1P-induced 
αSMA/transgelin up-
regulation; 
↓ S1P-activated L-type 
Ca2+ currents  
↓ S1P-induced 
differentiation to 
smooth muscle 
phenotype 
[197] 
3T3-L1 
adipocytes 
JTE-013 
(0.02-2 µM, during 
adipogenesis) 
↓ S1P-induced down- 
regulation of PPARγ, 
C/EBPα and adiponectin  
↑ adipogenesis  
↑ lipid 
accumulation  
[198] 
3T3-L1 
adipocyte 
JTE-013 (10µM, 1 
h P-ERK; 24 h 
proliferation)  
↑ P-ERK  ↑ adipocyte 
proliferation 
[199] 
3T3-
F442A 
adipocyte 
VPC-23019 
(10µM, 5 d) 
↑ adipocyte-specific gene 
expression (Fabp4, Lpl, 
Adipoq) 
↑ adipogenic 
differentiation 
[199] 
3T3-L1 
adipocytes 
siRNA S1P2 ↓ S1P-induced 
downregulation of PPARγ 
and P-JNK 
↓ S1P-mediated 
inhibition of lipid 
accumulation  
[200] 
3T3-L1 
adipocytes 
DMS or DHS 
(5 µM, 8 d of 
differentiation) 
↓ AP2 (mRNA)  ↓ adipogenesis and 
lipid accumulation 
[201] 
3T3-L1 
adipocytes 
SKI-II 
(10 µM, during 
adipogenesis) 
Not detected  ↓ lipogenesis and 
differentiation  
[202] 
3T3-L1 
adipocytes 
siRNA SphK1 ↓ (mRNA) AP2, PPARγ, 
C/EBPα  
↓ adipogenesis and 
lipid accumulation 
[201] 
S1P2-/-
mice 
HFD for 4 weeks  ↑ PCNA expression  ↑ adipocyte 
hyperplasia 
[199] 
Male 
C57B/6J 
DIO mice 
FTY720 
(0.04 mg/kg, i.p. 2x 
per w; 6 w) 
↓ HFD-induced AKT and 
AMPK dephosphorylation;   
↑ HSL, perilipin, ATGL, 
and HSL phosphorylation  
↓ fat accumulation  
↑ lipolysis 
[190] 
 
*AMSC, adipose tissue-derived mesenchymal stem cells; d, day; h, hour; m, minute; w, week 
Table 2. S1P and downstream signaling in adipose inflammation 
Cell type 
or animal 
Intervention Downstream signal Biological outcome Reference 
3T3-L1 
adipocytes 
S1P 
(50, 100 nM, 3 h) 
↑ TNF-α and KC 
↑ IL-6 
↑ proinflammatory 
cytokine secretion  
[95] 
C57BL/6 
male DIO 
mice 
FTY720 (1 or 3 
mg/kg, i.p., 8 w) 
↓ circulating 
monocytes 
↓adipose 
inflammation 
phenotype 
[204] 
Zucker 
lean 
normo-
glycemic 
control 
(ZLC) rats 
SPHK I 
(10 mg/kg, i.p., 
60 m before LPS 
(10 mg/kg)) 
↓ LPS-induced CCL5 
↓up-regulation of 
inflammation markers 
(Cd68, Cd163, Il-6, 
CCL2, and TNFα) in 
white adipose tissue 
↓ LPS-induced 
adipose 
inflammation 
↓ serum CCL5  
[212] 
C57BL/6 
male DIO 
mice 
SKI-II 
(20 mg/kg, i.p.) 
↓ isoproterenol- and 
CL-316243-mediated 
IL-6 upregulation  
↓ ADRB3/HSL-
mediated adipose 
inflammation  
[213] 
sphk1-/- 
mice 
HFD (16 w) ↑ PPARγ, AP2, 
GLUT4 
↓PPARγ Ser112 
phosphorylation 
↓ TNFα, IL-6, and 
MCP-1, SOCS3  
↑ IL-10, adiponectin  
↑ adipogenesis,  
↓ adipose 
inflammation 
↑ insulin sensitivity 
[172] 
DIO mice 5c 
(2mg/kg, i.p., 1x 
per d, 3d) 
↑ insulin-mediated  
P-AKT  
↓ (mRNA) TNFα, IL-
6, MCP-1, SOCS3 
↑ (mRNA) IL-10, 
adiponectin  
↑ glucose hemostasis  
↓ adipose 
inflammation 
[172] 
S1P2-/-
mice 
HFD for 4 weeks  abolish HFD-induced 
upregulation of M1 
macrophage markers 
(Cd11c and Nos2) 
↓ M1 macrophage 
recruitment  
[199] 
 





